Emideltide
Delta Sleep-Inducing Peptide Analog
Emideltide is a peptide people usually talk about for Chronic insomnia and Narcolepsy. It is still in the FDA review process, so people are watching both the research and the access question closely.
Why does this matter?
Emideltide matters because a lot of people hear about it online without a clear sense of what it may actually help with. This page gives you the plain-English version first, then shows where the research is strongest, what is still uncertain, and where the peptide stands in the FDA review process.
Molecular weight
848.81 g/mol
Molecular formula
C₃₅H₄₈N₁₀O₁₅
Amino acid count
9
Review date
July 23-24, 2026
Sequence / structure
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Other names
DSIP (Delta Sleep-Inducing Peptide), Emideltide (INN), Delta sleep peptide, Deltaran (Russian clinical formulation), Factor S (historical)
Status
Under FDA review for opioid withdrawal, insomnia, and narcolepsy
Emideltide, often called DSIP, is a natural sleep peptide that people study for deeper rest and calmer nights. It shows up most in discussions about insomnia, stress, and nervous-system recovery, with an especially interesting role in opioid withdrawal support and narcolepsy. That mix of sleep and recovery benefits is why it crosses over between everyday wellness conversations and the addiction-medicine world.
The quick version before the deep dive
- •People usually talk about Emideltide for Chronic insomnia and Narcolepsy.
- •Narcolepsy.
- •Helps promote delta (slow-wave) sleep architecture without suppressing REM.
- •Helps trigger luteinizing hormone and growth hormone release during sleep.
Deep Dive: Mechanism of Action +
Delta Wave Enhancement — Promotes delta (slow-wave) sleep architecture without suppressing REM
LH/GH Modulation — Stimulates luteinizing hormone and growth hormone release during sleep
Opioid System Modulation — Interacts with opioid receptors; modulates endorphin and enkephalin activity without direct agonism
Cortisol/ACTH Suppression — Blunts stress-induced cortisol and ACTH release
Serotonin Modulation — Influences serotonergic pathways related to sleep-wake cycles
Circadian Rhythm Regulation — Normalizes disrupted circadian patterns
Glutamate System — Modulates excitatory neurotransmission (relevant to withdrawal symptoms)
Temperature Regulation — Lowers core body temperature (associated with sleep onset)
Anti-oxidative — Limits free radical production under stress conditions
Where people usually see it discussed
Sleep Disorders (FDA Review Indications) +
- Chronic insomnia (primary indication)
- Narcolepsy
- Disrupted sleep architecture
- Shift work sleep disorder
- Circadian rhythm disorders
Addiction Medicine (FDA Review Indication) +
- Opioid withdrawal symptom management
- Alcohol withdrawal
- Benzodiazepine withdrawal
- Drug-induced sleep disruption
Stress & Mental Health +
- Chronic stress/PTSD
- Anxiety disorders
- Depression (adjunctive)
- Burnout syndrome
Pain +
- Chronic pain modulation
- Headache/migraine
- Fibromyalgia (experimental)
Performance/Recovery +
- Athletic recovery optimization
- Post-surgical sleep quality
- Jet lag
Formal evidence and study snapshots
Deep Dive: Clinical Trials +
Schneider-Helmert 1984
Human clinicalChronic insomnia
Improved sleep quality in 7 of 10 insomnia patients without tolerance
Kovalzon et al. (multiple)
Human clinicalSleep/narcolepsy
Deltaran nasal spray improved sleep parameters
Khaunina & Kolotilova 1992
Human clinicalAlcohol withdrawal
Reduced withdrawal severity scores
Dick et al. 1984
Human clinicalPain/stress
Reduced ACTH and cortisol responses
Russian clinical programs
Clinical useInsomnia/withdrawal
Deltaran approved and used clinically in Russia
What the current safety discussion looks like
- ✓Endogenous neuropeptide — Naturally present in human brain and blood
- ✓No dependence or tolerance reported with repeated use (unlike benzodiazepines/Z-drugs)
- ✓No respiratory depression (unlike opioid sleep aids)
- ✓No next-day hangover effects reported
- ✓No cognitive impairment observed
- ✓Well-tolerated in all published human studies
- ✓Side effects (rare): Mild headache, occasional vivid dreams
- ✓No abuse potential identified
- ✓Decades of clinical use in Russia without significant safety signals
- ✓Short half-life (~15-25 minutes in blood, but effects persist hours — likely due to receptor-level changes)
How the status timeline currently reads
Pre-2023
Category 1 — eligible for 503A compounding
September 2023
Moved to Category 2
Ongoing
Used clinically in Russia (Deltaran)
April 2026
FDA announces PCAC review
July 23-24, 2026
Advisory committee review for opioid withdrawal, chronic insomnia, and narcolepsy
How dosing is usually described
Subcutaneous/Intramuscular
Insomnia: 100-250 mcg before bedtime Withdrawal support: 100-300 mcg/day during acute withdrawal phase
Intranasal (Deltaran model)
Sleep: 100-300 mcg intranasally 30 minutes before desired sleep Advantage: Rapid absorption, crosses BBB effectively
Intravenous (Clinical setting)
Research doses: 25-50 mcg/kg (hospital setting only)
Duration
Insomnia: Can be used nightly without tolerance development Withdrawal: 7-14 days during acute phase
Research protocols only. Not medical advice.
The citations behind the page
Deep Dive: Key Research Papers +
- 1
Schoenenberger GA, Monnier M.*. "Characterization of a delta-electroencephalogram sleep-inducing peptide." Proceedings of the National Academy of Sciences 1977.
- 2
Schneider-Helmert D, Schoenenberger GA.*. "Effects of DSIP in man: multifunctional psychophysiological properties." Neuropsychobiology 1983.
- 3
Prudchenko IA, Mikhaleva II.*. "Chemistry of delta sleep-inducing peptide and its analogs." Bioorganicheskaia Khimiia 1994.
- 4
Graf MV, Kastin AJ.*. "Delta-sleep-inducing peptide (DSIP): a review." Neuroscience & Biobehavioral Reviews 1984.
- 5
Schneider-Helmert D.*. "Clinical evaluation of DSIP." European Neurology 1984.
- 6
Kovalzon VM, Strekalova TV.*. "Delta sleep-inducing peptide (DSIP): a still unresolved riddle." Journal of Neurochemistry 2006.
- 7
Khaunina RA, Kolotilova AI.*. "DSIP-like immunoreactive material in rat brain during alcohol withdrawal." Bulletin of Experimental Biology and Medicine 1992.
- 8
Dick P, et al.*. "DSIP in the treatment of withdrawal syndromes from alcohol and opiates." European Neurology 1984.
Common questions about Emideltide
What is Emideltide? +
Emideltide is Delta Sleep-Inducing Peptide Analog, one of the peptides currently under review in connection with opioid withdrawal, insomnia, and narcolepsy.
What is Emideltide being reviewed for? +
The current advisory review focuses on opioid withdrawal, insomnia, and narcolepsy, with a listed review date of July 23-24, 2026.
Which category does Emideltide belong to? +
Emideltide is grouped in this library under Sleep.
How many amino acids are in Emideltide? +
Emideltide is presented here as a 9-amino-acid peptide or peptide analog based on the source research and naming conventions.
What is the sequence or structure note for Emideltide? +
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu.
What research applications are most associated with Emideltide? +
Chronic insomnia, Narcolepsy, Disrupted sleep architecture, and Shift work sleep disorder
How is Emideltide described as working in the current research? +
Helps promote delta (slow-wave) sleep architecture without suppressing REM. Helps trigger luteinizing hormone and growth hormone release during sleep.
How is Emideltide usually discussed in protocols or treatment plans? +
Emideltide is most often described with subcutaneous/muscle injection and intranasal protocols in the source material.
What does the safety discussion say about Emideltide? +
Endogenous neuropeptide — Naturally present in human brain and blood No dependence or tolerance reported with repeated use (unlike benzodiazepines/Z-drugs)
Continue the comparison
Epitalon
Epitalon is a peptide people usually talk about for Aging & Longevity: Used to delay the onset of age-related physical and cognitive decline by preserving cellular lifespan via telomere maintenance. and Sleep Disorders: Applied to correct disrupted circadian rhythms and treat insomnia, leveraging its direct action on the melatonin pathway.. It is still in the FDA review process, so people are watching both the research and the access question closely.
Semax
Semax is a peptide people usually talk about for Cerebral ischemia / stroke recovery and Trigeminal neuralgia. It is still in the FDA review process, so people are watching both the research and the access question closely.
BPC-157
BPC-157 is a peptide people usually talk about for Ulcerative colitis and Inflammatory bowel disease. It is still in the FDA review process, so people are watching both the research and the access question closely.
Get notified when Emideltide becomes available
Join the waitlist for peptide-specific updates, regulatory milestones, and access news connected to the GobyMeds care pathway.